Iovance Biotherapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Iovance Biotherapeutics

23/02/2024 11:09

* Iovance Biotherapeutics Inc  IOVA.OQ   IOVA.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 28 for the period ending December 31 2023
    * The San Carlos California-based  company is expected to
report
revenue of $1.391 million, according to the mean estimate from
13 analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Iovance Biotherapeutics
Inc is
for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Iovance
Biotherapeutics Inc is $24.50​, above​ its last closing price
of $15.94. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.46       -0.45      -0.46     Missed  -1.3
 Jun. 30 2023  -0.82       -0.80      -0.47     Beat    41
 Mar. 31 2023  -0.77       -0.74      -0.50     Beat    32.9​
 Dec. 31 2022  -0.63       -0.64      -0.64     Met     -0.4
 ​​Sep.        -0.63       -0.64      -0.63     Beat    1.2
 30 2022                                                
 Jun. 30 2022  -0.59       -0.61      -0.63     Missed  -3.9​
 Mar. 31 2022  -0.64       -0.64      -0.58     Beat    8.9
 Dec. 31 2021  -0.56       -0.56      -0.63     Missed  -12.9
 This summary was machine generated February 23 at 11:09 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)